Hospital's pathology lab to serve Canadian and other North American translational-research customers that require studies run in a CLIA/ISO 9001-accreditation laboratory for regulatory submissions
WELLESLEY, Mass., Sept. 23 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that the Mt. Sinai Services unit of the Mt. Sinai Hospital in Toronto, Canada, has become an authorized provider of gene-expression services using Xceed's Ziplex System. The Mt. Sinai Hospital reference laboratory is a CLIA laboratory, accredited by the College of American Pathologists, and ISO 9001-certified by the Ontario Laboratory Accreditation Program.
"The Mt. Sinai Hospital's Department of Pathology and Laboratory Medicine has a worldwide reputation as a center of excellence for the highest-quality laboratory services to support the clinical and translational-research needs of the medical community," said Xceed President and CEO, David Deems. "This partnership enables Xceed to expand our service offerings to additional customers in Canada and North America that need their studies performed in a CLIA laboratory for regulatory submissions. In addition, Mt. Sinai will be an important partner for our own continued product-development work, providing both samples and services to help us validate new Xpress Chips(TM) in development for a wide range of disorders."
Mount Sinai Services Managing Director, Dr. Kenneth Pritzker, said, "This is an exciting time in translational medicine and Mt. Sinai has a long-standing commitment to supporting the next diagnostic breakthroughs and improved patient care with our services and the latest, most-advanced technology. The automated Ziplex System is an important addition to our laboratory, enabling us to standardize and streamline gene-expression services, while saving valuable staff time and ensuring the most reliable results. We look forward to working with Xceed and assuming a leadership role in providing gene expression analytical services."
The Ziplex System is rapidly becoming the standard platform for the nation's leading institutions performing translational research. Xceed designed the Ziplex System with turnkey functionality and significant advances in automation, array format, fluidics, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites.
About Xceed Molecular (http://www.XceedMolecular.com)
Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, and pre-configured arrays -- Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.
About Mt. Sinai Hospital (http://www.mountsinai.on.ca)
As one of Canada's pre-eminent patient care, research and academic
health science centres and one of Greater Toronto's Top 50 Employers, Mount
Sinai Hospital has a well-earned reputation for excellence in the community
and also well beyond its borders. It focuses on three broad organizational
goals:
-- Patient and family-centered care;
-- Increasing its role as an academic health sciences centre and teaching
hospital fully affiliated with the University of Toronto; and
-- Enhancing its community health partnerships
SOURCE Xceed Molecular Copyright©2008 PR Newswire. All rights reserved |